- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01349036
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma
February 18, 2020 updated by: Daiichi Sankyo, Inc.
A Phase 2 Study of Orally Administered PLX3397 in Patients With Recurrent Glioblastoma
The objective of this study is to evaluate the response of subjects with recurrent glioblastoma to continuous therapy of PLX3397.
Study Overview
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University California, Los Angeles
-
San Francisco, California, United States, 94143
- University California, San Francisco
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Faber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- University of Texas, MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, United States, 84132
- Huntsman Cancer Institute University of Utah
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female patients ≥18 years old with a life expectancy of at least 8 weeks
- Radiographically proven recurrent (≥ first relapse), intracranial Glioblastoma (GBM)
- For all patients, availability of at least 10 unstained slides (or archival tumor block sufficient to generate at least 10 unstained slides) from any previous GBM surgery
- Previous treatment with external beam radiation and temozolomide chemotherapy
- Before the first dose of PLX3397,adequate recovery from toxicity of prior therapy as follows:
>28 days for cytotoxic therapy >42 days for nitrosoureas >28 days for bevacizumab >7 days for non cytotoxic therapy such as interferon, tamoxifen, thalidomide, cis-retinoic acid, or erlotinib
- Women of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ≥1 year. Men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug.
- Karnofsky performance status of ≥60
- Adequate hematologic, hepatic, and renal function (absolute neutrophil count ≥1.0 x 109/L, Hgb >9 g/dL, platelet count ≥50 x 109/L, Aspartate aminotransferase/Alanine aminotransferase (AST/ALT) ≤2.5x Upper Limit of Normal (ULN), creatinine ≤1.5x ULN)
- Willing and able to provide written informed consent prior to any study related procedures and to comply with all study requirements
Exclusion Criteria:
- Investigational drug use within 28 days of the first dose of PLX3397
- GBM progression within 3 months of previous radiation by Response Assessment in Neuro-Oncology (RANO) criteria
- History of Grade 2 Common Toxicity Criteria for Adverse Events (CTCAE v4) or greater acute intracranial hemorrhage
- Previous failure of bevacizumab or other vascular endothelial growth factor (VEGF) therapy except in a first line setting
- History of malignant glioma with co-deletion of 1p/19q
- A concurrent active cancer that requires non-surgical therapy (e.g. chemotherapy, radiation, adjuvant therapy). Prior history of other cancer is allowed, as long as there was no active disease within the prior 3 years.
- Refractory nausea and vomiting, malabsorption, biliary shunt, or significant bowel resection that would preclude adequate absorption
- Patients with serious illnesses, uncontrolled infection, medical conditions, or other medical history including abnormal laboratory results, which in the investigator's opinion would be likely to interfere with a patient's participation in the study, or with the interpretation of the results
- Women of child-bearing potential who are pregnant or breast feeding
- corrected QT interval (QTc) ≥450 msec at Screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PLX3397-Cohort 1
10 patients with recurrent glioblastoma who require reoperation will be treated with PLX3397 for 7 days prior to surgery and their tumor tissue will be evaluated for pharmacokinetic levels and pharmacodynamic effects.
|
Capsules administered once or twice daily, continuous dosing
Other Names:
|
EXPERIMENTAL: PLX3397-Cohort 2
30 patients will be orally dosed with PLX3397 continuously on 28 day cycles.
|
Capsules administered once or twice daily, continuous dosing
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Summary of Response Rates in Participants on Treatment With PLX3397
Time Frame: 6 months post dose
|
Response to treatment was evaluated using the Response Assessment in Neuro-Oncology (RANO) criteria.
All participants were evaluated for progression free survival (PFS), and overall survival (OS).
The six-month PFS rate was defined as the number of subjects with PFS of at least 6-month duration, with PFS measured from the first day of treatment (Cycle 1, Day 1) to the date of the first documented disease progression or date of death, whichever occurs first, over a 6-month period and evaluated using the Kaplan Meier method.
The rate of OS was defined as the number of subjects that survived until study exit.
|
6 months post dose
|
Mean Plasma Pharmacokinetic Parameters of PLX3397 After Oral Administration of 1000 mg/Day - Cycle 1 Day 15
Time Frame: Pre-dose and up to 6 post dose during cycle 1, Day 15
|
A noncompartmental method of analysis was used to analyze the plasma concentrations of PLX3397.
Mean plasma pharmacokinetic parameters, include time to maximum concentration (Tmax) and will be calculated from the Cycle 1, Day 15 values.
|
Pre-dose and up to 6 post dose during cycle 1, Day 15
|
Mean Plasma Pharmacokinetic Parameters of PLX3397 After Oral Administration of 1000 mg/Day - Cycle 1 Day 15
Time Frame: Pre-dose and up to 6 post dose during cycle 1, Day 15
|
A noncompartmental method of analysis was used to analyze the plasma concentrations of PLX3397.
Mean plasma pharmacokinetic parameters include maximum concentration (Cmax) and will be calculated from the Cycle 1, Day 15 values.
|
Pre-dose and up to 6 post dose during cycle 1, Day 15
|
Mean Plasma Pharmacokinetic Parameters of PLX3397 After Oral Administration of 1000 mg/Day - Cycle 1 Day 15
Time Frame: Pre-dose and up to 6 post dose during cycle 1, Day 15
|
A noncompartmental method of analysis was used to analyze the plasma concentrations of PLX3397.
Mean plasma pharmacokinetic parameters include an assessment of area under the curve over 0-4 hours (AUC0-4), and will be calculated from the Cycle 1, Day 15 values.
|
Pre-dose and up to 6 post dose during cycle 1, Day 15
|
Mean Plasma Pharmacokinetic Parameters of PLX3397 After Oral Administration of 1000 mg/Day - Cycle 1 Day 15
Time Frame: Pre-dose and up to 6 post dose during cycle 1, Day 15
|
A noncompartmental method of analysis was used to analyze the plasma concentrations of PLX3397.
Mean plasma pharmacokinetic parameters include an assessment of area under the curve over 0-6 hours (AUC0-6), and will be calculated from the Cycle 1, Day 15 values.
|
Pre-dose and up to 6 post dose during cycle 1, Day 15
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence (Number and Percentage of Participants) With Treatment-Emergent Adverse Events Related to Study Drug Occurring in ≥10% Participants During Treatment With PLX3397 (Safety Population)
Time Frame: Up to 1 year post dose
|
Up to 1 year post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
December 3, 2011
Primary Completion (ACTUAL)
November 5, 2013
Study Completion (ACTUAL)
November 5, 2013
Study Registration Dates
First Submitted
May 4, 2011
First Submitted That Met QC Criteria
May 5, 2011
First Posted (ESTIMATE)
May 6, 2011
Study Record Updates
Last Update Posted (ACTUAL)
March 3, 2020
Last Update Submitted That Met QC Criteria
February 18, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PLX108-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/.
In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants.
Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD Sharing Time Frame
Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD Sharing Access Criteria
Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research.
This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Glioblastoma
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); University of California, Los Angeles; Oncoceutics...WithdrawnRecurrent Glioblastoma | Recurrent Gliosarcoma | Recurrent Supratentorial Glioblastoma | Supratentorial GliosarcomaUnited States
-
Massachusetts General HospitalNot yet recruitingGlioblastoma Recurrent, EGFR vIII Mutant | Newly Diagnosed Glioblastoma, EGFRvIII Mutant | Recurrent Glioblastoma, EGFR vIII NegativeUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Glioblastoma, IDH-Wildtype | MGMT-Methylated Glioblastoma | Recurrent MGMT-Methylated GlioblastomaUnited States
-
University of OklahomaGlaxoSmithKlineTerminatedRecurrent Glioblastoma | Recurrent Glioma | Recurrent Astrocytoma | Recurrent OligodendrogliomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Glioblastoma | Giant Cell Glioblastoma | Recurrent GliosarcomaUnited States
-
University of Michigan Rogel Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Newly Diagnosed Glioblastoma | Recurrent Gliosarcoma | Recurrent Astrocytoma, Grade IV | Newly Diagnosed Gliosarcoma | Newly Diagnosed Astrocytoma, Grade IVUnited States
-
Center for Neurosciences, TucsonGenentech, Inc.CompletedRecurrent Glioblastoma Multiforme | Recurrent GliosarcomaUnited States
-
Northwestern UniversityBristol-Myers Squibb; Lantheus Medical Imaging; CarTheraRecruitingGlioblastoma | Glioblastoma Multiforme | Gliosarcoma | GBM | Recurrent Glioblastoma | Glioblastoma, IDH-wildtypeUnited States
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Jonsson Comprehensive Cancer CenterBristol-Myers Squibb; Northwest Biotherapeutics; Brain Tumor Funders CollaborativeWithdrawnGliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Small Cell Glioblastoma | Giant Cell GlioblastomaUnited States
Clinical Trials on PLX3397
-
Daiichi Sankyo, Inc.PlexxikonCompleted
-
Daiichi Sankyo, Inc.PlexxikonTerminatedProstate CancerUnited States
-
Daiichi Sankyo, Inc.PlexxikonCompletedHodgkin LymphomaUnited States
-
Daiichi Sankyo Co., Ltd.Daiichi SankyoActive, not recruitingMelanomaKorea, Republic of, China
-
Daiichi Sankyo Co., Ltd.RecruitingTenosynovial Giant Cell TumorJapan
-
The Christie NHS Foundation TrustCancer Research UK; Christie Charitable FundsCompleted
-
Daiichi Sankyo, Inc.PlexxikonCompletedAcute Myeloid LeukemiaUnited States
-
Daiichi Sankyo Co., Ltd.Active, not recruitingTenosynovial Giant Cell TumorTaiwan, China
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell TumorUnited States, Spain, Taiwan, Australia, Hungary, Italy, Netherlands
-
Daiichi Sankyo, Inc.CompletedTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Giant Cell Tumors of the Tendon SheathUnited States, France, Australia, Denmark, Spain, Netherlands, Germany, Canada, United Kingdom, Hungary, Italy, Poland